These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 2114021)

  • 1. Evaluation of free tissue concentrations of fleroxacin after oral administration.
    Limberg J; LeBel M; Derendorf H
    Pharm Res; 1990 Apr; 7(4):422-4. PubMed ID: 2114021
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics and tissue penetration of fleroxacin after single and multiple 400- and 800-mg-dosage regimens.
    Panneton AC; Bergeron MG; LeBel M
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1515-20. PubMed ID: 3142338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
    Kees F; Naber KG; Schumacher H; Grobecker H
    Chemotherapy; 1988; 34(6):437-43. PubMed ID: 2468456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative oral pharmacokinetics of fleroxacin and pefloxacin.
    De Lepeleire I; Van Hecken A; Verbesselt R; Tjandra-Maga TB; De Schepper PJ
    J Antimicrob Chemother; 1988 Aug; 22(2):197-202. PubMed ID: 3141343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo tissue pharmacokinetics by fluorine magnetic resonance spectroscopy: a study of liver and muscle disposition of fleroxacin in humans.
    Jynge P; Skjetne T; Gribbestad I; Kleinbloesem CH; Hoogkamer HF; Antonsen O; Krane J; Bakøy OE; Furuheim KM; Nilsen OG
    Clin Pharmacol Ther; 1990 Nov; 48(5):481-9. PubMed ID: 2121409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and tissue penetration of Ro 23-6240, a new trifluoroquinolone.
    Wise R; Kirkpatrick B; Ashby J; Griggs DJ
    Antimicrob Agents Chemother; 1987 Feb; 31(2):161-3. PubMed ID: 3105446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
    Lubowski TJ; Nightingale C; Sweeney K; Quintiliani R; Zhi J
    Antimicrob Agents Chemother; 1992 Mar; 36(3):651-5. PubMed ID: 1622179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of the penetration of two quinolones into intra-abdominal abscess.
    Tudor RG; Youngs DJ; Yoshioka K; Burdon DW; Keighley MR
    Arch Surg; 1988 Dec; 123(12):1487-90. PubMed ID: 3142444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The metabolism and pharmacokinetics of fleroxacin in healthy subjects.
    Griggs DJ; Wise R; Kirkpatrick B; Ashby JP
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():191-4. PubMed ID: 3144537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered disposition of fleroxacin in patients with cystic fibrosis.
    Mimeault J; Vallée F; Seelmann R; Sörgel F; Ruel M; LeBel M
    Clin Pharmacol Ther; 1990 May; 47(5):618-28. PubMed ID: 2111750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single- and multiple-dose pharmacokinetics of fleroxacin, a trifluorinated quinolone, in humans.
    Weidekamm E; Portmann R; Suter K; Partos C; Dell D; Lücker PW
    Antimicrob Agents Chemother; 1987 Dec; 31(12):1909-14. PubMed ID: 3125788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of Ro 23-6240 (AM 833), a new trifluorinated quinolone.
    Weidekamm E; Stöckel K; Dell D
    Chemioterapia; 1987 Jun; 6(2 Suppl):307-8. PubMed ID: 3151346
    [No Abstract]   [Full Text] [Related]  

  • 13. Fleroxacin concentrations in myometrium, ovary and fallopian tube.
    Portmann R; Hansz C; Stiglmayer R; Weidekamm E
    J Antimicrob Chemother; 1989 Apr; 23(4):662-4. PubMed ID: 2501273
    [No Abstract]   [Full Text] [Related]  

  • 14. The comparative pharmacokinetics and tissue penetration of single-dose ciprofloxacin 400 mg i.v. and 750 mg po.
    Catchpole C; Andrews JM; Woodcock J; Wise R
    J Antimicrob Chemother; 1994 Jan; 33(1):103-10. PubMed ID: 8157550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fleroxacin in single dose oral therapy of uncomplicated lower urinary tract infection.
    Kosmidis J; Gargalianos P; Adamis G; Petropoulou D; Makris D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():219-21. PubMed ID: 3144541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single and multiple dose pharmacokinetics of fleroxacin.
    Weidekamm E; Portmann R; Partos C; Dell D
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid-chromatographic determination of fleroxacin in serum and urine.
    Awni WM; Maloney JA; Heim-Duthoy KL
    Clin Chem; 1988 Nov; 34(11):2330-2. PubMed ID: 3141086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
    Naber KG; Sörgel F; Kees F; Schumacher H; Metz R; Grobecker H
    J Antimicrob Chemother; 1988 Oct; 22 Suppl D():199-207. PubMed ID: 2462556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Steady-state pharmacokinetics of fleroxacin in patients with skin and skin structure infections.
    Heim-Duthoy K; Peltier G; Awni W
    Antimicrob Agents Chemother; 1990 May; 34(5):922-3. PubMed ID: 2113797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bacteriological and clinical studies on fleroxacin in male gonococcal urethritis].
    Saito I; Suzuki A; Yokozawa M; Ono K; Miyamura R; Hamaya O
    Hinyokika Kiyo; 1991 Jun; 37(6):663-8. PubMed ID: 1909831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.